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Abstract
Background: The farnesoid X receptor (FXR), a ligand-activated transcription factor belonging to the adopted
orphan receptor, plays an important role in maintaining health of the liver and intestine. In this study, we identified
individual bacterial strains that directly modulated the activation of intestinal FXR.
Methods: The FXR stimulatory potential of 38 bacterial strains was determined using a stable FXR reporter system
derived from intestinal epithelial cells (IEC). The induction of FXR target genes by screened FXR stimulatory bacteria
was determined by real-time PCR. In addition, a high fat diet (HFD)-induced obese mouse model was used to
evaluate in vivo FXR stimulatory potential of bacterial metabolites screened in this study.
Results: A luciferase assay with the FXR reporter cell line demonstrated that the FXR-stimulatory activity of most
bacterial cell samples was less than 2-fold. The culture supernatants of Bacteroides dorei and Eubacterium limosum
induced FXR activity and selectively regulated FXR target expression in the FXR reporter system. Treatment with
B. dorei-derived metabolites strongly induced ileal bile acid binding protein (IBABP) (8.4-fold) and organic solute
transporter (OST) α (3.1-fold) compared with E. limosum-derived metabolites. Furthermore, administration of B. dorei
derived metabolites showed significant reduction in body weight gain, and both two bacterial metabolites reduced
liver weight in obese mice compared to PBS-treated controls. Administration of each bacterial metabolites
improved in serum levels of obesity-related metabolic biochemical markers such as ALT, AST, total cholesterol, and
triglyceride. Furthermore, two bacterial metabolites enhanced the Fxr gene expression in the intestine and liver, and
ileal Shp gene expression tended to be increased by treatment with the metabolites derived from B. dorei.
Conclusions: B. dorei and E. limosum secreted the bioactive substances that directly stimulate FXR in the intestinal
epithelial cells. Administration of these bacterial FXR-stimulatory metabolites improves the obesity phenotype
including body weight gain, liver damage, lipid metabolism in DIO mice.
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Background
Farnesoid X receptor (FXR, NR1H4) is a ligand-
activated transcription factor belonging to the adopted
orphan receptor [1]. It is abundantly expressed in the
liver, intestine, kidney, and adrenals [2, 3], but is also
expressed in fat, the stomach, lungs and heart [3, 4].
FXR mainly regulates intracellular levels of bile acids
(BAs) in the liver and intestine though various genes dir-
ectly and intervenes in other nuclear receptor signaling
pathways [5, 6]. Other studies have demonstrated that
FXR activates a series of genes involved in lipid and glu-
cose homeostasis and plays a crucial role in reducing
diabetes [7, 8]. Recent evidence showed that FXR activa-
tion is critical in the regulation of inflammatory
responses [9–11].
FXR is a promiscuous receptor activated by many
compounds not only BAs [12]. The activation of FXR by
its ligands is effective for many diseases as demonstrated
by in vitro and in vivo studies. FXR activation with the
synthetic agonist GW4064 induced a significant reduc-
tion in hepatic and serum triglycerides levels [7, 13, 14],
and very low density lipoprotein secretion was decreased
by increased small heterodimer partner (SHP) expression
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in mouse models of obesity and type 2 diabetes [15]. A
lower incidence and extent of necrosis, reduced in-
flammation, and depressed bile duct proliferation was
observed in rats treated with GW4064 [16]. The FXR
potent agonist 6α-ethyl-chenodeoxycholic acid
(6ECDCA) protected mice from lithocholic acid-
induced cholestasis [17]. In addition, 6ECDCA has
anti-inflammatory effects in inflammatory bowel dis-
ease. It inhibited inflammation and preserved the in-
testinal barrier by inhibiting proinflammatory
cytokines, such as tumor necrosis factor-α [10]. In
contrast, FXR-deficiency in mice leads to increased
colon cell proliferation and carcinogenesis [18], con-
tributes to liver tumor formation [19] and causes im-
paired glucose tolerance and insulin sensitivity [20].
Because of its important role in BA homeostasis and
other metabolic diseases, FXR has the potential to be
an attractive therapeutic target for common metabolic
disease treatment or prevention.
However, the clinical use of FXR ligands is not cur-
rently approved. The most potent FXR ligand is
6ECDCA, which is under investigation in a phase clinic
study, and a long-term safety extension program is
planned [21]. Two recent studies investigating the effect
of FXR activation by GW4064 on high fat diet-induced
obesity and glucose intolerance showed contrasting re-
sults [22, 23]. The underlying molecular mechanisms
contributing to these differences or FXR signaling path-
ways are not fully understood, thus it is necessary to
identify potent and selective FXR ligands or modulators
that will provide us with a powerful tool to elucidate the
complex mechanisms of FXR signaling.
Many types and numbers of bacteria inhabit the hu-
man body, which aid the maintenance of human me-
tabolism homeostasis. Gut bacteria protect against
obesity and insulin resistance [24], attenuate inflam-
mation and restore colon homeostasis [25]. BAs levels
were reduced in the gallbladder and small intestine in
the presence of gut microbiota compared with germ
free mice [26, 27]. Previous mouse studies indicated
an association between gut microbiota and FXR func-
tion [28]. Gut microbiota regulate BAs homeostasis
by altering the BAs composition resulting in FXR ac-
tivation in the intestine and liver [29]. In addition, a
recent study showed functional FXR activity was ne-
cessary for the probiotic VSL#3 to exert its activity
on BAs excretion and neosynthesis in mice [30].
When investigating how gut microbiota affect relevant
diseases via FXR activation, the use of individual bac-
terial strains is useful because of the complexity of
using whole gut microbiota. Therefore, we aimed to
identify individual bacterial strains from the intestine
that might have important and unexpected functions
via direct FXR activation.
Methods
Cell culture
A human colon adenocarcinoma cell line SW480
(ECACC, N0. 87092801), liver hepatocellular cell line
HepG2 (ECACC, No. 85011430) and epithelial colorectal
adenocarcinoma cell line CaCO-2 (ECACC, No.
86010202) were grown at 37 °C with 5 % CO2 in high-
glucose Dulbecco’s modified Eagle’s medium (DMEM;
Wako, Osaka, Japan), supplemented with 10 % heat-
inactivated fetal bovine serum (Invitrogen, Grand Island,
NY) and 1 % Penicillin-Streptomycin Solution (×100)
(Wako).
Preparation of bacterial suspensions and bacterial
culture supernatant
Thirty-eight bacterial isolates were used in this study
(Table 1). Each bacterial isolate was identified based on a
nearly full 16S rRNA sequence, which was deposited in
the DNA Data Bank of Japan. Bacterial strains were cul-
tivated in GAM medium (Nissui, Tokyo, Japan) for 40 h
in anaerobic conditions, and then the culture broth was
centrifuged at 9000 rpm for 10 min to separate bacteria
pellets and culture supernatants. After washing with
10 ml phosphate buffered saline (PBS) twice, the wet
weight of bacteria pellets was measured. Then, bacteria
pellets were suspended in PBS at a final concentration of
100 mg/ml as follows: PBS (ml) =W× 9, [W (g) = wet
weight of bacteria pellets]. Bacterial suspensions of
0.5 ml were added to 0.2 g of 0.1 mm silica/zirconium
beads (BioSpec Products, Bartlesville, OK) that were
centrifuged at 5500 rpm for 2 min to disrupt bacteria.
Bacterial suspensions were heat-killed at 100 °C for
10 min. Intact bacterial suspensions were directly pre-
served. Bacterial culture supernatant was filtered
through cellulose acetate filters with a pore size of
0.2 μm (ADVANTEC Toyo, Tokyo, Japan) to remove
bacteria from the supernatant. All samples were stored
at −80 °C.
FXRE-driven firefly luciferase reporter vector
A DNA fragment containing four copies of the FXR elem-
ent (FXRE: 5′-aaactgaGGGTCAgTGACCCaaggtgaa-3′)
from the phospholipid transfer protein promoter [31, 32]
and XhoI and BglII restriction enzyme sites was synthe-
sized and cloned into the vector pUC19 (Greiner Bio-One,
Frickenhausen, Germany). The XhoI/BglII fragment of
pUC19-4 × FXRE was ligated into a pGL4.27 [luc2p/minP/
Hygro] vector (Promega, Madison, WI) and digested with
XhoI/BglII (Promega) to generate a FXRE-driven firefly lu-
ciferase reporter vector (pGL4-4 × FXRE-luc).
Establishment of a stable FXR reporter cell line
SW480 cells do not respond to treatment with a FXR
agonist (e.g. GW4064), because SW480 cells do not
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endogenously express FXR [33]. To generate a stable
FXR expressing cell, SW480 cells were transfected with
a FXR expression vector EX-T0601-M02 (Genecopeia,
Rockville, MD) using FuGENE reagent (Promega). For
the selection of stable FXR expressing cells, cells were
cultured in DMEM medium containing 800 μg/ml G418
(Wako). G418-resistant SW480 cells were further trans-
fected with a reporter vector pGL4-4 × FXRE-luc with
Table 1 Bacteria used in this study
Strain Accession number Isolation source Taxonomic assignment 16S rRNA sequence similarity (%)
W1 Culture collections Lactobacillus casei [NBRC 15883] -
W2 Culture collections Lactobacillus fermentum [NBRC 15885] -
W3 Culture collections Lactobacillus plantarum [NBRC 15891] -
W4 Culture collections Lactococcus lactis [NBRC 100933] -
W5 LC061609 Dairy foods Lactobacillus gasseri [FJ557004] 99
W6 LC061610 Dairy foods Lactobacillus delbrueckii [CP000156] 99
W7 LC061611 Dairy foods Streptococcus thermophilus [FR875178] 99
W8 LC061612 Dairy foods Lactobacillus helveticus [CP011386] 99
W9 LC061613 Dairy foods Lactobacillus gasseri [FJ557004] 99
W10 LC061614 Dairy foods Streptococcus thermophilus [FR875178] 99
W11 LC061615 Dairy foods Lactobacillus reuteri [EU722746] 99
W12 LC033789 Dairy foods Lactobacillus helveticus [HM218413] 99
W13 (WU 12)a AB932539 Human feces Bifidobacterium bifidum [AP012323] 100
W14 (WU 16)a AB932540 Human fces Bifidobacterium longum [FP929034] 100
W15 (WU 22)a AB932542 Human feces Bifidobacterium adolescentis [CP010437] 99
W16 (WU 57)a AB932544 Human feces Bifidobacterium bifidum [KJ160509] 99
W18 LC033790 Human feces Bacteroides dorei [EU722737] 99
W19 LC033791 Human feces Eubacterium limosum [AB638446] 99
W20 LC033792 Human feces Bacteroides sp.W20 [EU728710] 99
W21 LC033793 Human feces Bacteroides fragilis [AB618792] 98
W22 LC033794 Human feces Ruminococcus sp.W22 [FJ611794] 99
W23 LC033795 Human feces Clostridiales bacterium W23 [HQ452859] 98
W24 LC033796 Human feces Bacteroides uniformis [AB247142] 99
W25 LC033797 Mouse feces Parabacteroides distasonis [AB238924] 98
W26 LC033798 Mouse feces Bacteroides acidifaciens [AB510696] 97
W27 LC033799 Mouse feces Bacteroides thetaiotaomicron [AE015928] 97
W28 LC033800 Mouse feces Lactobacillus johnsonii [FN298497] 99
W29 LC033801 Mouse feces Lactobacillus reuteri [KR492886] 97
W30 LC033802 Mouse feces Lactobacillus animalis [AB911535] 98
W31 LC033803 Mouse feces Bacteroides sartorii [AB572597] 98
W32 LC033804 Mouse feces Bacteroides sp.W32 [AB599946] 99
W33 LC033805 Mouse feces Parabacteroides goldsteinii [AB547650] 99
W34 LC033806 Mouse feces Enterococcus faecalis [FJ378702] 99
W35 LC033807 Human feces Enterococcus durans [AJ276354] 99
W36 (WU 27)a AB932524 Human feces Enterococcus raffinosus [AF061003] 99
W37 (WU 65)a AB932534 Human feces Enterococcus cecorum [AF061009] 99
W38 (WU 76)a AB932546 Human feces Enterococcus avium [DQ779961] 100
W39 LC033808 Human feces Enterococcus faecium [FJ378690] 99
aThese strains are the same as those previously reported [44]
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FuGENE transfect reagent. For the selection of a stable
FXR reporter vector cell, the cells were cultured in
DMEM medium containing 800 μg/ml G418 and
300 μg/ml hygromycin B (Invitrogen). G418 and hygro-
mycin B-resistant cells were collected with a cloning
cylinder, and subcultured into fresh medium containing
G418 and hygromycin B.
Reporter assay
FXR reporter cells were seeded at a density of 5 × 104
cells/well (96-well plates). Twenty-four hours after seed-
ing, cells were incubated with bacterial suspensions, cul-
ture supernatants, dimethyl sulfoxide (DMSO, 0.1 % v/v)
or GW4064 (10 μM) respectively for 24 h. Then, cell su-
pernatants were removed and cells were washed twice
with phosphate-buffered saline (PBS) and lysed by add-
ing 20 μl of passive lysis 5 × buffer (Promega) with gentle
rocking for 20 min. Luciferase activity was measured by
the administration of luciferase assay reagent (Promega)
using a GloMax® 96 Microplate Luminometer (Pro-
mega). The ratio of treatment over control was used
to determine the fold activation.
RNA isolation and Real-time PCR
Cells (3 × 105 cells/well) were seeded in a 24-well plate
24 h before the administration of bacterial supernatant
samples. After 24 h of incubation with bacterial super-
natant samples, total RNA was extracted from cells
using a Qiagen RNeasy mini kit (Qiagen, Tokyo, Japan).
RNA concentration and purity were determined by a
NanoDrop™ spectrophotometer (Thermo Scientific, Wal-
tham, MA). For reverse transcription reactions, 1 μg of
total RNA was used in a final volume of 20 μl with Pri-
meScript RT reagent Kit (Takara, Tokyo, Japan) at 37 °C
for 15 min and 85 °C for 5 s. Real-time PCR reactions
were performed using the iCycler iQ™ Real-Time PCR
Detection System (Bio-Rad, Hercules, CA). For each re-
action, the final volume of 20 μl contained 10 μl of SYBR
Green PCR Mix (Bio-Rad), 1 μl of each primer (10 μM)
(Table 2), and 2 μl of RT product diluted 10 times. After
PCR, melting curve analysis was performed to ensure
the specificity of the assay. Each analysis was performed
in triplicate and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as endogenous gene. Relative
gene expression was calculated via the Relative standard
curve method [34].
In vivo study
Four-week-old C57BL/6 J male mice were obtained from
CLEA Japan. Mice were housed in a temperature-
controlled room (23 °C) under a 12 h light–dark cycle.
The mice were given standard diet (STD; CLEA Japan,
Tokyo, Japan) for 1 week before high fat diet (HFD;
CLEA Japan) administration for another 10 weeks. Mice
were also administered bacterial culture supernatants
(0.1 ml) per day by intragastric administration. Body
weight was recorded and HFD intake was estimated
weekly. Mice were sacrificed after 11 weeks of bacterial
culture supernatants intervention. Tissues were collected,
snap-frozen in liquid nitrogen and stored at −80 °C until
analyzed. Total RNA was isolated from the ileum and liver
using a Qiagen RNeasy mini kit after homogenization
(Microtec, Chiba, Japan). Serum levels of aspartate amino-
transferase (AST), alanine aminotransferase (ALT), total
cholesterol, glucose, triglyceride were determined with a
SPOTCHEM™ EZ SP-4420 analyzer (Arkray, Tokyo,
Japan). All experiments were approved by the Waseda
University Academic Research Ethics Committee.
Results
Stable FXR reporter cell line construction
To monitor FXR transcriptional activity in an intestinal
epithelial cell line, we constructed a stable FXR reporter
cell line by cotransfecting a reporter vector pGL4-
4xFXRE-luc and human FXR expression vector into
SW480 cells. Nine single cell clones isolated from the
transfected cell populations were used to determine the
responsiveness to synthetic FXR agonist (GW4064).
Each FXR reporter cell clone was treated with 10 μM
GW4064 or DMSO as a control. Clone 9 was selected
because it had a high relative luminescent unit (RLU)
and signal-to-background (S/B) ratio (Fig. 1a). The re-
sponsiveness of SW480 cells transfected with the re-
porter vector pGL4-4xFXRE-luc to 10 μM GW4064
was very low (S/B ratio = 2), indicating that endogen-
ous FXR expression level in SW480 cells is low. Thus,
agonist-induced luciferase induction in FXR reporter
cells constructed in this study was due to exogenous
FXR expression.
Next, FXR reporter cells were exposed to different
concentrations of FXR agonist GW4064 to characterize
agonist dose-responses (Fig. 1b). The level of FXR re-
porter activity increased in a dose-dependent manner.
Furthermore, we determined whether stimulation with
FXR agonist could transactivate FXR target genes in
FXR reporter cells. GW4064 induced the gene expres-
sion of ileal bile acid binding protein (Ibabp), organic
solute transporter α (Ostα) and fibroblast growth factor
19 (Fgf19) in a dose-dependent manner (Figs. 1c-e). The
mRNA levels of the gene Ibabp and Ostα reached a
maximum expression level at 500 nM GW4064, while
the expression of the Fgf19 gene reached a peak of
expression at 100 nM GW4064.
Screening of FXR-stimulating bacteria by luciferase assay
By using a FXR reporter cell (clone 9), a total of 38 bac-
terial strains, which were affiliated with the genera Bac-
teroides, Bifidobacterium, Enterococcus, Eubacterium,
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Lactobacillus, Parabacteroides, Ruminococcus and
Streptococcus, were assessed to determine whether they
could modulate FXR activation (Fig. 2). FXR-stimulatory
potentials of intact bacterial cells, mechanical disrupted
bacterial cells, heat-killed bacterial cells, or bacterial cul-
ture supernatants of each isolate were evaluated using
FXR reporter cells. Intact bacteria maintained the inte-
gral part of the bacterial outer membrane, whereas frac-
tionated subcellular components were exposed when
bacteria were disrupted by beating with beads. Heat
treatment of bacterial cells leads to conformational
changes and the degradation of bacterial cell wall com-
ponents. FXR-stimulatory activities of most bacterial
cell samples showed less than 2-fold changes. Inter-
estingly, culture supernatants derived from B. dorei
and E. limosum intensely activated FXR, which indi-
cated that these two bacteria might function as FXR
modulators (Fig. 2d).
Evaluation of FXR-stimulating bacteria
By repeating three independent experiments in triplicate,
we confirmed the reproducibility of the FXR-stimulatory
activity of culture supernatants derived from B. dorei
and E. limosum (Fig. 3a). As a result, 10 % of B. dorei
culture supernatant strongly induced FXR activation,
whereas the FXR-stimulatory potential of E. limosum
was similar to that of 10 nM GW4064. Next, the FXR-
stimulatory activities of bacterial culture supernatants
were sampled every 12 h and bacterial cell growth dur-
ing cultivation was determined (Figs. 3b, c). The FXR-
stimulatory potential of B. dorei in culture super-
natant increased continuously with the growth of bac-
terial cells. In contrast, the FXR-stimulatory potential
of E. limosum in the culture supernatant began to
increase after 12 h and reached a plateau at 36 h.
Induction of FXR target genes by bacterial culture
supernatants
We determined whether the culture supernatants of B.
dorei and E. limosum induced FXR target gene expres-
sion in FXR reporter cells. As shown in Fig. 4, culture
supernatants derived from both B. dorei and E. limosum
transactivated the FXR target genes Ibabp and Ostα.
Interestingly, treatment with B. dorei-derived metabo-
lites strongly induced Ibabp mRNA (8.4-fold) and Ostα
(3.1-fold) compared with E. limosum-derived metabo-
lites. Nevertheless, neither of these two culture superna-
tants induced Fgf19 mRNA expression in FXR reporter
cells. These results indicated that FXR activation in-
duced by treatment with these bacterial metabolites did
not induce the transactivation of all FXR target genes.
Specificity of FXR regulation by two bacterial metabolites
Due to multiple possibilities of luciferase activity induc-
tion, the specificity of FXR activation by two bacterial
metabolites was validated in cells with or without FXR
Table 2 Sequences of primers used in this study
Gene Forward Reverse Reference
GAPDH GAAGGTGAAGGTCGGAGT CATGGGTGGAATCATATTGGAA [45]
IBABP TCACTTGGTCCCAGCACTA CTTGTCACCCACGATCTCT [45]
OSTα CTACACCTGGGTGAGCAGAA AGAGGAATAGGGAGGCGAAC [46]
FGF19 CACGGGCTCTCCAGCTGCTTCCTGCG TCCTCCTCGAAAGCACAGTCTTCCTCCG [47]
SHP GGCTGGCAGTGCTGATTCAG TGGGGTGTGGCTGAGTGAAG [48]
Gapdh AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA [22]
Fxr TCCAGGGTTTCAGACACTGG GCCGAACGAAGAAACATGG [27]
Ibabp CAGGAGACGTGATTGAAAGGG GCCCCCAGAGTAAGACTGGG [27]
Ostα TGTTCCAGGTGCTTGTCATCC CCACTGTTAGCCAAGATGGAGAA [27]
Fgf15 ACGTCCTTGATGGCAATCG GAGGACCAAAACGAACGAAAT T [27]
Cyp7a1 AGCAACTAAACAACCTGCCAGTACTA GTCCGGATATTCAAGGATGCA [27]
Cyp7b1 TAGCCCTCTTTCCTCCACTCATA GAACCGATCGAACCTAAATTCCT [27]
Cyp8b1 GGCTGGCTTCCTGAGCTTATT ACTTCCTGAACAGCTCATCGG [27]
Shp CGATCCTCTTCAACCCAGATG AGGGCTCCAAGACTTCACACA [27]
Bsep CTGCCAAGGATGCTAATGCA CGATGGCTACCCTTTGCTTCT [27]
Ntcp ATGACCACCTGCTCCAGCTT GCCTTTGTAGGGCACCTTGT [27]
Ibat ACCACTTGCTCCACACTGCTT CGTTCCTGAGTCAACCCACAT [27]
Genes in capitals indicate human genes, and those in lower case are mouse genes. Gapdh, Ibabp and Ostα were analyzed using the following conditions: 95 °C
2 min, 40 cycles of 95 °C for 10 s, and 60 °C for 30 s. Fgf19 was analyzed using the following conditions: 95 °C 15 min, 40 cycles of 95 °C for 15 s, and 62 °C for
30 s. All mouse genes were analyzed using the following conditions: 95 °C 2 min, 40 cycles of 95 °C for 15 s, and 60 °C for 60 s
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expression. As shown in Fig. 5a, two bacterial metab-
olites did not induce FXR activity in FXR null
SW480 cells, indicating that the chemiluminescense
activity stimulated by two bacterial metabolites is
dependent on FXR. In addition, the levels of FXR
target gene Ibabp and Ostα were very low compared
with that in FXR containing cells (Figs. 5b, c), indi-
cating that FXR target genes expression by two bac-
terial culture supernatants is dependent on FXR in
SW480 cells.
To investigate whether two bacterial metabolites ac-
tivation FXR target genes in other cell lines, we used
two different cell lines (i.e. Caco-2, HepG2), which
endogenously express FXR [33, 35, 36]. Two bacterial
culture supernatants induced the Ibabp gene expres-
sion (Figs. 5d, e). The levels of Ibabp gene expression
were consistent with differentiation degree of Caco-2
cells. However, two bacterial metabolites did not in-
duce the Ibabp gene expression in FXR null-SW480
cells. Also, the culture supernatant derived from B.
dorei did not stimulate FXR of a hepatocyte-derived
cell line, HepG2 cells, by measuring the Shp gene
that induced directly by FXR activation (Fig. 5f ).
Beneficial effects of daily administration of bacterial
metabolites in diet-induced obese (DIO) mice
To investigate whether B. dorei and E. limosum FXR-
derived metabolites conferred anti-obesity effects, they
were daily administrated to diet-induced obese mice fed
with high-fat diet (HFD). Mice body weight recorded
every week is shown in Fig. 6a. HFD dramatically elevated
mice body weight compared to STD. Since 6 weeks of ad-
ministration of B. dorei derived-metabolites (the period of
HFD intake, 5 weeks), the mice showed lower body weight
compared with mice that received PBS only, indicating
that B. dorei culture metabolites may help mice to be re-
sistant to the body weight gain. In contrast, the mice that
received those of E. limosum did not show any significant
differences in body weight gain. Long-term administration
of each bacterial metabolite had a reducing effect of liver
weight in DIO mice (Fig. 6b). Especially, administration
of E. limosum-derived metabolites led to a significant
reduction in liver weight compared with the PBS con-
trol group. On the other hand, DIO mice treated with
B. dorei-derived metabolites tended to reduce liver
weight compared with the PBS control group, but this
was not statistically significant.
a b
c d e
Fig. 1 Construction of a stable FXR reporter cell line. Cells were seeded to white 96-well plates with density of 5 × 104/well 24 h before
administration of GW4064 or DMSO. After 24 h cultivation, cells were lysed and chemiluminescense was evaluated by administration of luciferase
assay reagent: (a) RLU and S/B ratio. (b) Dose response of FXR agonist (GW4064). (c-e) mRNA expression of FXR target genes, Ibabp (c), Ostα (d),
Fgf19 (e) by GW4064. Gapdh was used as endogenous gene. Gene expression levels were calculated via the relative standard curve method.
Experiments were performed in triplicate with the mean ± SD shown. RLU: Relative luminescent units; S/B: Signal noise ratio = GW4064/DMSO =
Relative FXR stimulatory potential




Fig. 2 Screening of FXR-stimulating bacteria. After cells were cultured in white 96-well plates with density of 5 × 104/well for 24 h, bacterial
suspensions or culture supernatants were introduced for 24 h incubation before measurement of chemiluminescense by administration of
luciferase assay reagent. (a) Intact bacteria. (b) Mechanical disrupted bacteria. (c) Heat-killed bacteria. (d) Culture supernatants. Experiments were
performed in triplicate. Values are the mean ± SD
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Daily administration of each bacterial metabolites
had improvement in serum biochemical markers of
liver functions (Figs. 6c-g). Compared to PBS-treated
DIO mice, AST levels decreased significantly in mice
treated with metabolites derived from B. dorei. Fur-
thermore, E. limosum-derived metabolites have a great
improvement in serum levels of ALT, total choles-
terol, and triglyceride. These results suggest that
FXR-stimulatory bacterial metabolites can improve the
metabolic conditions in DIO mice.
We also determined whether alive bacterial cells of
two FXR-stimulatory bacteria promote the metabolic
improvement in DIO mice. However, the mice treated
with alive bacterial cells per week were significantly
indistinguishable from the PBS-treated mice in regard
to body weight gain, liver weight, serum biomarkers
(Additional file 1: Figure S1).
Bacterial metabolite-induced modulation of FXR
target genes
To determine whether the administration of FXR-
stimulatory bacteria affected the regulation of FXR target
genes in vivo, we measured mRNA expression levels of
Fxr target genes in the ileum and liver (Fig. 7). The HFD
intake did not affect ileal or hepatic Fxr expression
levels, while enhanced the expression levels of ileal Shp
(3.7-fold), hepatic Shp (1.8-fold) and Bsep (1.4-fold)
compared with PBS-treated DIO mice. Administration
of two bacterial metabolites induced Fxr expression in
both ileum and liver (Figs. 7a, g). E. limosum-derived
a b c
Fig. 3 Evaluation of two FXR-stimulating bacteria. After cells were cultured in white 96-well plates with density of 5 × 104/well for 24 h, bacterial
culture supernatants were introduced for 24 h incubation before measurement of chemiluminescense by administration of luciferase assay
reagent: (a) FXR activation by culture supernatants of B. dorei and E. limosum, (b) FXR activation by culture supernatants sampled at various times,
(c) The quantity of two bacterial cells at different times. Values are the mean ± SD (n = 3). *p < 0.05 compared to the GAM group
a b c
Fig. 4 mRNA expression of FXR target genes induced by B. dorei or E. limosum. Cells were cultured in 24-well plates with density of 3 × 105/well
for 24 h, bacterial culture supernatants were introduced for 24 h incubation before total RNA isolation. mRNA levels were normalized to Gapdh mRNA
levels via the relative standard curve method: (a) Ibabp expression levels, (b) Ostα expression levels, (c) Fgf19 expression levels. Values are the mean ±
SD (n = 3). Differences compared with the GAM culture treatment group were calculated using Student’s t-test (*p < 0.05, **p < 0.01, ***p < 0.001)
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metabolites significantly up-regulated the expression of
ileal bile acid transporter (Ibat, 2.5-fold) and Na+-tauro-
cholate cotransporting polypeptide (Ntcp, 1.4-fold), but
decreased the expression of ileal Shp (0.2-fold) and hep-
atic Shp (0.5-fold). B. dorei-derived metabolites signifi-
cantly increased the ileal Ibat expression (1.9-fold).
These results indicate that two different bacterial metab-
olites can modulate the expression of FXR target genes
in a tissue- and gene-specific manner.
We also determined whether administration of alive
bacterial cells of B. dorei and E. limosum alter the expres-
sion of FXR target genes in DIO mice (Additional file 2:
Figure S2). As a result, the administration of alive bacterial
cells enhanced ileal Fxr mRNA expression, while had no
effect on other FXR target genes in the ileum and liver.
Discussion
In the present study, we investigated whether bacteria or
bacterial metabolites could modulate FXR activation. Our
results indicated that culture supernatants of B. dorei and
E. limosum induced FXR activity and selectively induced
the expression of FXR target genes in IEC. We also found
that the administration of culture supernatants of B. dorei
and E. limosum to DIO mice increased Fxr activity and se-
lectively regulated the expression of Fxr target genes in
both ileum and liver. The present study showed for the
first time that bacterial culture supernatants directly in-
duce FXR activity and the expression of FXR target genes.
Cell-based reporter assays are widely used for the
screening of FXR agonists or antagonists isolated from
natural or synthetic compounds. Most FXR reporter
a b c
d e f
Fig. 5 Intestinal epithelial cell-specific FXR activation of two bacterial metabolites. FXR-expressed or FXR-null SW480 cells were treated with
bacterial culture supernatants (10 % v/v) for 24 h incubation before measurement of by administration of luciferase assay reagent. (a) The
activation of FXR in each cell was measured by luciferase reporter construct FXRE-Luc (n = 2). The induction of FXR target gene by bacterial
culture supernatants was determined with quantitative real-time reverse transcription-PCR analysis (n = 1): (b) Ibabp gene, (c) Ostα gene. (d, e) The
culture supernatant derived from B. dorei transactivated FXR target gene (Ibabp) in Caco-2 cells (n = 1). Before the treatment with bacterial
supernatants, cells were cultured for 7 days or 21 days. The induction of FXR target gene (Ibabp) by bacterial culture supernatant were determined in
undifferentiated (d) or fully differentiated Caco-2 cells (e). (f) The FXR stimulatory potential of bacterial supernatants FXR in HepG2 cells. Shp gene
expression levels in HepG2 cells treated with bacterial culture supernatant were determined (n = 1). mRNA levels were normalized to Gapdh mRNA
levels via the relative standard curve method. Relative mRNA expression: Compared to DMEM medium group. Experiments were performed in
triplicate. Values are the mean ± SD. Differences were calculated using Student’s t-test (*p < 0.05, **p < 0.01, ***p < 0.001)
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cells used in previous studies were derived from
hepatocyte-derived cell line (HepG2) or human embry-
onic kidney cell line (HEK293), but not IECs [35, 36]. In
the present study, an IEC-based FXR reporter system
was developed for the identification of gut bacteria that
modulate intestinal FXR signaling. The expression and
function of FXR in IECs are important factors for the con-
struction of an IEC-based FXR reporter system. Gottardi
et al. conducted a comparative evaluation on the level of
FXR expression among commonly-used human colonic
carcinoma cell lines (Caco-2, HT-29, SW480, SW620) and
reported the dependency of FXR expression levels on cel-
lular differentiation [33]. In this report, the level of FXR
expression in Caco-2 and HT-29 cells changed with their
degree of differentiation, which might affect the repeat-
ability and reproducibility of the assay system. Although
SW480 or SW620 cells did not endogenously express
FXR, when these cell lines were transiently transfected
with the expression vector for FXR, they could normally
transactivate FXR target genes by stimulation with a FXR
agonist. Thus, the stable transfection of SW480 cells with
an expression vector for human FXR and a FXRE-
luciferase reporter construct is important for IEC-based
FXR reporter systems with high reproducibility and super-
ior signal-to-background ratio. Furthermore, two bacterial
metabolites did not induce chemiluminescense activity in
SW480 cells without FXR expression, indicating that two
bacterial metabolites contain a FXR agonist. In addition,
B. dorei and E. limosum screened using IEC-based FXR
reporter cells induced FXR target gene Ibabp expression
in Caco-2 cells but did not activate FXR signal transduc-
tion in a HepG2 cell line that expresses FXR endogenously
with normal functions [37]. These results indicate that
IEC-based FXR reporter cell is useful for screening intes-
tinal FXR modulators including bacteria.
FXR activation in the intestine and liver directly in-
duces the expression of genes regulating the transport of
bile acids (BAs) (e.g. Bsep, IBABP, OSTα), while the
genes involved in the synthesis (e.g. Cyp7a1, Cyp8b1)
and re-absorption (e.g. Ibat, Ntcp) of BAs are repressed
a
c d e f g
b
Fig. 6 Effects of FXR-stimulatory metabolites on the phenotypes in diet-induced obesity mice. Mice fed with high fat diet (HFD) were treated
bacterial culture supernatants (0.1 ml) by intragastric administration. (a) Body weight changes during the experimental period. (b) Liver weight
changes after 10 weeks of the treatment. (c-g) Serum biochemical markers. Values are the mean ± SEM (standard diet-fed group, N = 3; HFD-fed
group, N = 6). Differences compared to HFD-PBS group were calculated using Student’s t-test (*p < 0.05, **p < 0.01, ***p < 0.001)
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through SHP and FGF15/19 induced by FXR activation
[38]. Two bacterial metabolites enhanced the Fxr gene
expression in the intestine and liver, and ileal Shp gene
expression tended to be increased by treatment with the
metabolites derived from B. dorei. However, the expres-
sion of most FXR target genes were not positively regu-
lated by intragastric administration of the bacterial
supernatants. Rather, E. limosum-derived metabolites
significantly repressed ileal and hepatic expression of
Shp and up-regulated the expression of Ibat and
Ntcp. Furthermore, the administration of alive bacter-
ial cells had little influence on the expression of the
FXR target genes. The difference between in vitro and
in vivo experiments might be affected by the
colonization and metabolic activities of FXR-
stimulatory bacteria in the ileum. Previous studies
showed that the composition of BAs, which are
strongly affected by gut microbiota, modulated FXR-
mediated gene expression in vivo [27, 28, 30, 39].
Thus, the alteration in gut microbiota by FXR-stimulating
bacterial metabolites might also influence the regulation
of FXR target gene expression. In future study, we need to
investigate whether BAs metabolism and gut microbiota
are influence by the administration of FXR-stimulatory
bacteria or metabolites.
Intestinal FXR signaling might be a drug target for
obesity and metabolic complications (e.g. non-
alcoholic fatty liver disease). In this study, HFD-fed
mice treated with FXR-stimulating bacterial metabo-
lites (B. dorei) helped mice to be resistant to obesity
compared with control mice. Furthermore, in vivo ad-
ministration of FXR-stimulating bacterial metabolites
decreased the levels of serum biochemical markers for
liver injury (i.e. ALT, AST) and lipid metabolism (i.e.
cholesterol, triglyceride) in DIO mice. At present,
there are contradictory reports on the role of intes-
tinal FXR signaling in metabolic improvement. One
potential mechanism is that the inhibition of intes-
tinal FXR signaling improves obesity and insulin re-
sponsiveness in HFD-fed mice [28]. Previous reports
a
g h i j k l m
b c d e f
Fig. 7 Effects of FXR-stimulatory metabolites on intestinal and hepatic expression of FXR target genes. (a-f) mRNA levels in the ileum. (g-m)
mRNA levels in the liver. mRNA levels were normalized to Gapdh mRNA levels via the relative standard curve method. Values are the mean ± SEM
(N = 6). Differences from the PBS treatment group were calculated using Student’s t-test (*p < 0.05, **p < 0.01)
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showed that diet-induced weight gain or metabolic
defects were suppressed in intestine-specific FXR-null
mice [28]. It was also reported that the anti-obesity
effect was associated with the inhibition of intestinal
FXR signaling by the accumulation of tauro-β-
muricholic acid (TβMCA), which is an endogenous
antagonist of FXR [27]. The accumulation of TβMCA
is caused by the depletion or decrease of gut micro-
biota that possess BAs deconjugation ability. However,
intestinal FXR activation with the FXR agonist fexara-
mine enhanced energy expenditure mediated through
the activation of β-adrenergic receptor signaling in
adipose tissues, resulting in metabolic improvement in
DIO mice [39]. The intestinal-selective effect of FXR
might be coordinated by the induction of intestinal endo-
crine hormone fibroblast growth factor 15 (FGF15, homo-
log of FGF19 in humans) [27, 30, 39–42]. We showed
that the administration of bacterial cells or metabo-
lites of B. dorei tended to enhance the expression of
ileal Fgf15 gene compared with the PBS-treated group
although this was not statistically significant. This
suggests that the concentration of FXR agonist in the
supernatants or the frequency of bacteria might be
inadequate to achieve metabolic improvement in DIO
mice. Further studies are required to evaluate whether
metabolic improvement is enhanced by the increased
administration frequency of bacterial cells or adminis-
tration of FXR agonists purified from bacterial culture
supernatants.
Intestinal FXR activation has the potential of cur-
ing intestinal bowel disease (IBD) as well as meta-
bolic disorders [9, 10]. A previous report showed
that intestinal inflammation was associated with a
decrease Fxr expression levels in the inflamed intes-
tinal mucosa of Crohn’s disease and experimental
colitis mice [9]. Polymorphisms in the FXR gene
were not associated with IBD pathogenesis [43].
Thus, intestinal FXR activation could have a thera-
peutic effect on IBD. Interestingly, the expression
level of Fxr mRNA in the ileum was enhanced by
treatment with both FXR-stimulating bacteria
screened in this study. In future experiments, we will
evaluate whether B. dorei or E. limosum exerts a
curative effect on intestinal inflammation using ex-
perimental colitis mouse models.
In summary, this study has been successful in
screening two distinct gut bacteria secreted metabo-
lites that directly transactivated FXR target genes in
IEC by using a cell-based assay. Long-term adminis-
tration of B. dorei-derived metabolites, which have
high FXR-stimulatory potential in vitro, suppress the
obese phenotype including weight gain and liver
damage in DIO mice. However, further studies are re-
quired to validate the effects and safety of FXR-
stimulatory bacteria or metabolites as a therapeutic
option for metabolic modulation in animal models.
Conclusions
In this study, we report that metabolites of B. dorei and
E. limosum induced FXR activity in a stable FXR re-
porter system, and selectively regulated FXR target gene
expression in vitro. Treatment of diet-induced obese
mice with B. dorei or E. limosum metabolites regulated
the expression of genes involved in BAs homeostasis in
a gene- and tissue-specific manner. Thus, these two bac-
teria have potential value as useful tools for the study of
complex FXR functions, and provide a novel therapeutic
direction for the treatment or prevention of common
metabolic disorders.
Additional files
Additional file 1: Figure S1. Effects of FXR-stimulatory bacteria on the
phenotypes in diet-induced obesity mice. HFD-fed Mice fed with high fat
diet (HFD) were treated with alive bacterial cells (109 bacteria) by intragastric
administration. (A) Body weight changes during the experimental period.
(B) Liver weight changes after 10 weeks of the treatment. (C-G) Serum
biochemical markers. Values are the mean ± SEM (standard diet-fed group,
N = 3; HFD-fed group, N = 6). Differences compared to HFD-PBS group
were calculated using Student’s t-test (*p < 0.05, **p < 0.01, ***p <
0.001). (PPTX 75 kb)
Additional file 2: Figure S2. Effects of FXR-stimulatory bacteria on
intestinal and hepatic expression of FXR target genes. (A-F) mRNA
levels in the ileum. (B) mRNA levels in the liver. mRNA levels were
normalized to Gapdh mRNA levels via the relative standard curve
method. Values are the mean ± SEM, n = 6. Differences from the PBS
treatment group were calculated using Student’s t-test (*p < 0.05,
**p < 0.01). (PPTX 108 kb)
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